CHAPEL HILL, N.C., Sept. 26 /PRNewswire/ -- The landscape of scientific publications strategy, planning and delivery is changing with the advent of transparency guidelines. Half of global publications groups are fully located in the marketing function, but publications leaders foresee a shift to medical groups to increase clinical presentation, according to a new report released by Best Practices, LLC.
In a benchmarking study that included such influential companies as Pfizer, GlaxoSmithKline, Lilly and Merck, it was found that 14 percent of participating pharmaceutical and biotech companies avoid using global or regional marketing representatives to develop their global publications strategy. These companies, which align publications strictly within the medical group, receive strategic input from medical directors, advisor physicians and biostatisticians.
For a complimentary summary of the full report "Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance," click on the following link http://www3.best-in-class.com/rr790.htm. The study guides pharmaceutical and biotechnology companies in the transition to the new publishing environment to create the desired synergy between credibility of scientific rigor and increased commercial success.
Other key topic areas in the research include:
-- Impact of transparency guidelines on publications, planning and
-- Tactics for handling publication of neutral or negative clinical trial
-- Optimal structure for the global publications function
-- Transition of global publication function from commercial to clinical
-- Strategy changes for the new marketplace
Among the key topics gathered in this report are:
-- Centralization of publications strategy, planning and delivery
-- Trends surrounding region
|SOURCE Best Practices, LLC|
Copyright©2007 PR Newswire.
All rights reserved